Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing pharmacology, mechanisms, and literature without systematic review methodology.
PubMed 39254764 · doi:10.1007/s00018-024-05353-6
What was done
This narrative review synthesized existing evidence on the pharmacology, neurobiology, and clinical potential of N,N-dimethyltryptamine (DMT), both alone and in combination with monoamine oxidase A (MAO-A) inhibitors such as botanical β-carbolines in ayahuasca and synthetic formulations.
What was found
The abstract reports no original quantitative data or summary effect sizes. It details that DMT acts primarily via 5-HT1A/2A/2C receptor agonism, that MAO-A inhibition circumvents rapid first-pass metabolism to extend oral bioavailability, and that the combined mechanisms alter functional brain network dynamics and promote neuroplasticity.
Why it matters
Clarifying the synergistic pharmacology of DMT and MAO inhibitors helps frame mechanistic hypotheses for developing botanical and synthetic formulations targeted at depression, addiction, and post-traumatic stress disorder.
Limits
The study is a narrative review with no systematic methodology or primary patient data provided in the abstract. Quantitative clinical outcomes, dosing parameters, adverse effect frequencies, and sample sizes are not reported.
Cited by
- supports Ayahuasca combines dimethyltryptamine (DMT) with a monoamine oxidase (MAO) inhibitor, which prevents rapid metabolism in the gut and prolongs its duration of action.